Literature DB >> 24172097

Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC).

Stephanie L Wethington1, Kay J Park, Robert A Soslow, Noah D Kauff, Carol L Brown, Fanny Dao, Ebunoluwa Otegbeye, Yukio Sonoda, Nadeem R Abu-Rustum, Richard R Barakat, Douglas A Levine, Ginger J Gardner.   

Abstract

OBJECTIVE: Risk-reducing salpingo-oophorectomy (RRSO) is recommended for women with BRCA mutation due to increased risk of pelvic serous carcinoma. Serous tubal intraepithelial carcinoma (STIC) is a pathologic finding of unknown clinical significance. This study evaluates the clinical outcome of patients with isolated STIC. MATERIALS/
METHODS: We retrospectively reviewed the medical records of consecutive patients with a germline BRCA1/2 mutation or a high-risk personal or family history of ovarian cancer who underwent RRSO between January 2006 and June 2011. All patients had peritoneal washings collected. All surgical specimens were assessed using the sectioning and extensively examining the fimbria protocol, with immunohistochemistry when indicated. p53 signature lesions and secretory cell outgrowths were excluded.
RESULTS: Of 593 patients who underwent RRSO, isolated STIC was diagnosed in 12 patients (2%). Five patients (42%) were BRCA1 positive, 5 patients (42%) were BRCA2 positive, and 2 patients (17%) had high-risk family history. Preoperatively, all patients with STIC had normal CA-125 levels and/or pelvic imaging results. Seven patients underwent hysterectomy and omentectomy, 6 patients (46%) had pelvic node dissections, and 5 patients (39%) had para-aortic node dissections. With the exception of positive peritoneal washings in 1 patient, no invasive or metastatic disease was identified. No patient received adjuvant chemotherapy. At median follow-up of 28 months (range, 16-44 months), no recurrences have been identified.
CONCLUSIONS: Among the cases of isolated STIC after RRSO reported in the literature, the yield of surgical staging is low, and short-term clinical outcomes are favorable. Peritoneal washings are the most common site of disease spread. Individualized management is warranted until additional data become available.

Entities:  

Mesh:

Year:  2013        PMID: 24172097      PMCID: PMC4979072          DOI: 10.1097/IGC.0b013e3182a80ac8

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  29 in total

1.  Pathologic findings in prophylactic oophorectomy specimens in high-risk women.

Authors:  Katherine Leeper; Rochelle Garcia; Elizabeth Swisher; Barbara Goff; Benjamin Greer; Pamela Paley
Journal:  Gynecol Oncol       Date:  2002-10       Impact factor: 5.482

2.  The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.

Authors:  Ranjit Manchanda; Ronny Drapkin; Ian Jacobs; Usha Menon
Journal:  Gynecol Oncol       Date:  2011-10-20       Impact factor: 5.482

3.  Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.

Authors:  C B Powell; E M Swisher; I Cass; J McLennan; B Norquist; R L Garcia; J Lester; B Y Karlan; L Chen
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

4.  Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.

Authors:  C Bethan Powell; Lee-may Chen; Jane McLennan; Beth Crawford; Charles Zaloudek; Joseph T Rabban; Dan H Moore; John Ziegler
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

5.  Pathophysiology of the Fallopian tube.

Authors:  C J Pauerstein
Journal:  Clin Obstet Gynecol       Date:  1974-06       Impact factor: 2.190

6.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

7.  The pathological assessment of ovarian neoplasms. III: The malignant "epithelial" tumours.

Authors:  P Russell
Journal:  Pathology       Date:  1979-07       Impact factor: 5.306

8.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

9.  Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.

Authors:  Michael J Callahan; Christopher P Crum; Fabiola Medeiros; David W Kindelberger; Julia A Elvin; Judy E Garber; Colleen M Feltmate; Ross S Berkowitz; Michael G Muto
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

10.  Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.

Authors:  Welmoed Reitsma; Geertruida H de Bock; Jan C Oosterwijk; Joost Bart; Harry Hollema; Marian J E Mourits
Journal:  Eur J Cancer       Date:  2012-08-21       Impact factor: 9.162

View more
  24 in total

Review 1.  It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Authors:  Ruth Perets; Ronny Drapkin
Journal:  Cancer Res       Date:  2015-12-15       Impact factor: 12.701

2.  Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.

Authors:  James R Conner; Emily Meserve; Ellen Pizer; Judy Garber; Michael Roh; Nicole Urban; Charles Drescher; Bradley J Quade; Michael Muto; Brooke E Howitt; Mark D Pearlman; Ross S Berkowitz; Neil Horowitz; Christopher P Crum; Colleen Feltmate
Journal:  Gynecol Oncol       Date:  2013-12-12       Impact factor: 5.482

Review 3.  Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update.

Authors:  Felix Zeppernick; Ivo Meinhold-Heerlein; Ie-Ming Shih
Journal:  J Obstet Gynaecol Res       Date:  2014-10-20       Impact factor: 1.730

4.  An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.

Authors:  Marie E Perrone; Nicholas P Reder; Sergay N Agoff; Rochelle L Garcia; Kathy J Agnew; Barbara M Norquist; Kathryn P Pennington; Elizabeth M Swisher; Mark R Kilgore
Journal:  Int J Gynecol Pathol       Date:  2020-05       Impact factor: 2.762

Review 5.  Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Authors:  Anthony N Karnezis; Kathleen R Cho
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

Review 6.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

Review 7.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2016-04       Impact factor: 4.307

8.  Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries.

Authors:  Britton Trabert; Sally B Coburn; Andrea Mariani; Hannah P Yang; Philip S Rosenberg; Gretchen L Gierach; Nicolas Wentzensen; Kathy A Cronin; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2018-07-01       Impact factor: 13.506

9.  The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium.

Authors:  Gang Ning; Jonathan G Bijron; Yusuke Yamamoto; Xia Wang; Brooke E Howitt; Michael Herfs; Eric Yang; Yue Hong; Maxence Cornille; Lingyan Wu; Suchanan Hanamornroongruang; Frank D McKeon; Christopher P Crum; Wa Xian
Journal:  J Pathol       Date:  2014-09-30       Impact factor: 7.996

Review 10.  The tubal epigenome - An emerging target for ovarian cancer.

Authors:  Hunter D Reavis; Ronny Drapkin
Journal:  Pharmacol Ther       Date:  2020-03-18       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.